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Key messages
 ► Previous data from observational 
studies provided inconsistent evidence 
about the association between depot 
medroxyprogesterone acetate (DMPA) 
and HIV acquisition.
 ► New data from a high- quality 
randomised clinical trial found no 
statistically significant differences in 
HIV acquisition among DMPA users 
compared with implant users or copper 
intrauterine device users.
 ► Observational data continue to suggest 
no association between other hormonal 
contraception methods and HIV 
acquisition.
 ► The World Health Organization 
has updated recommendations on 
contraceptive use for women at high 
risk of HIV, based in part on this new 
evidence.
ABSTRACT
Objective To update a 2016 systematic review 
on hormonal contraception use and HIV 
acquisition.
Methods We searched Pubmed and Embase 
between 15 January 2016 and 26 June 2019 
for longitudinal studies comparing incident 
HIV infection among women using a hormonal 
contraceptive method and either non- users or 
users of another specific hormonal contraceptive 
method. We extracted information from newly 
identified studies, assessed study quality, and 
updated forest plots and meta- analyses.
Results In addition to 31 previously included 
studies, five more were identified; three 
provided higher quality evidence. A randomised 
clinical trial (RCT) found no statistically 
significant differences in HIV risk among users 
of intramuscular depot medroxyprogesterone 
acetate (DMPA- IM), levonorgestrel implant 
(LNG implant) or the copper intrauterine device 
(Cu- IUD). An observational study found no 
statistically significant differences in HIV risk 
among women using DMPA, norethisterone 
enanthate (NET- EN), implants (type not specified) 
or Cu- IUD. Updated results from a previously 
included observational study continued to find 
a statistically significant increased HIV risk with 
oral contraceptives and DMPA compared with 
no contraceptive use, and found no association 
between LNG implant and HIV risk.
Conclusions High- quality RCT data comparing 
use of DMPA, LNG implant and Cu- IUD does not 
support previous concerns from observational 
studies that DMPA- IM use increases the risk 
of HIV acquisition. Use of other hormonal 
contraceptive methods (oral contraceptives, 
NET- EN and implants) is not associated with an 
increased risk of HIV acquisition.
InTRoduCTIon
Observational epidemiological studies 
since 1991 have provided inconsistent 
evidence about a link between hormonal 
contraception use and HIV acquisition 
among women.1 2 Of particular concern 
has been the potential for increased 
risk of HIV acquisition associated with 
injectable depot medroxyprogesterone 
acetate (DMPA), a widely used contra-
ceptive method in some areas of the 
world where HIV incidence rates, and 
maternal morbidity and mortality rates, 
are high.2 3 The World Health Organi-
zation (WHO) has held several consul-
tations to review accumulating evidence 
and inform recommendations for safe 
contraception use among women at high 
risk of HIV, published in WHO’s Medical 
Eligibility Criteria for Contraceptive 
Use (WHOMEC).4 In 2016, a system-
atic review of epidemiological evidence 
on the association between hormonal 
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contraception use and HIV acquisition was conducted 
in preparation for a WHO consultation.2 That review 
included relevant evidence published to 15 January 
2016 from 31 observational studies. Most studies 
were considered “unlikely to inform the primary 
question” due to methodological limitations, and the 
review’s appraisal focused on 14 higher- quality studies 
deemed “informative but with important limitations”. 
The systematic review concluded that the evidence for 
most hormonal contraceptive methods did not suggest 
an association with HIV acquisition, but that new 
information had increased concerns about a possible 
association between DMPA and HIV risk. A key uncer-
tainty when interpreting the findings of these observa-
tional data was the possibility of unmeasured, residual 
confounding distorting the true association between 
DMPA use and HIV acquisition, particularly in rela-
tion to condom use and other sexual behaviours.
In June 2019, results from the Evidence for Contra-
ceptive Options and HIV Outcomes (ECHO) trial were 
published.5 The ECHO trial was a randomised clinical 
trial (RCT) specifically designed to compare HIV inci-
dence among users of three common contraceptives: 
intramuscular DMPA (DMPA- IM), levonorgestrel 
implant (LNG implant) and the copper intrauterine 
device (Cu- IUD), with the goal of minimising 
confounding through randomisation. We provide an 
update of the previous systematic review, including 
results from the ECHO trial and other new epidemi-
ological evidence reported since the last publication.
MeThodS
This systematic review adhered to the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analysis (PRISMA) guidelines.6 We followed the same 
methodology that was used in the previous systematic 
review,2 except where noted below. The review ques-
tion was: “Among women at risk of HIV, does use 
of a hormonal contraceptive method compared with 
non- use of a hormonal contraceptive method (or use 
of another specific hormonal contraceptive method) 
increase the risk of HIV acquisition?”.
Inclusion and exclusion criteria
We included studies of women of reproductive age at 
risk of HIV infection (ie, HIV- seronegative at baseline) 
that compared incident, laboratory- confirmed HIV 
infection among women using a hormonal contra-
ceptive method (all types of injectable, oral, implant, 
patch, ring, or the levonorgestrel- containing intrau-
terine device (LNG- IUD)), compared with women using 
a non- hormonal method (eg, condom, non- hormonal 
IUD, sterilisation, withdrawal) or no contraception. We 
also included studies comparing incident HIV infec-
tion among users of one specific hormonal contracep-
tive method compared with another specific hormonal 
contraceptive method (eg, DMPA users compared with 
norethisterone enanthate (NET- EN) users). We included 
longitudinal studies (observational studies, randomised 
trials, or meta- analyses containing data not previously 
published). Given the timing and location of the studies, 
we assumed that most, if not all, DMPA use in these 
studies was DMPA- IM rather than subcutaneous DMPA 
(DMPA- SC).
Search strategy
We searched Pubmed and Embase for the dates 15 
January 2016 (the cut- off date for the last system-
atic review) to 26 June 2019 (online supplementary 
appendix 1). We hand- searched reference lists of 
included studies. Three authors (TC, KC, PH) screened 
the abstracts and full- text articles using Covidence,7 
and conflicts were resolved through discussion.
data extraction and quality assessment
We used a data abstraction form to abstract data from 
any newly identified studies. The previous review used 
a study quality assessment framework that focused 
on observational studies.2 Briefly, studies that failed 
to adjust for condom use or that had unclear meas-
urement of hormonal contraception exposure were 
considered “unlikely to inform the primary question”; 
all other studies were considered “informative but 
with important limitations” to emphasise the poten-
tial for residual or uncontrolled confounding in these 
observational studies. For this review, we expanded the 
previous framework to include criteria for assessing 
RCTs and to define criteria for an additional higher- 
quality level of studies that were “informative with few 
limitations” (online supplementary appendix 2).8
Graphical summaries and meta-analysis
We updated the forest plots with all newly identified 
reports that were considered “informative but with 
important limitations” or “informative with few limita-
tions”. The forest plots present adjusted point estimates 
and confidence intervals (CIs) for each contraceptive 
method compared with a non- hormonal method or no 
contraception, or head- to- head comparisons between 
two specific hormonal methods. For reports in which 
authors presented estimates from more than one model, 
we used the most fully adjusted estimates.
We also updated the meta- analysis of observational 
studies assessing the association between DMPA 
(compared with no hormonal contraception) and 
risk of HIV. We determined a priori that it was not 
appropriate to combine estimates from observational 
studies and RCTs into a single meta- analysis, given 
differences in potential sources of bias.9 Meta- analyses 
were conducted in Stata version 17 (StataCorp, 
College Station, TX, USA). We included the most 
fully adjusted Cox hazards ratio (HR) estimates from 
each study. These point estimates and 95% CIs were 
log- transformed to calculate standard errors, using 
a random effects model.10 We evaluated statistical 
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heterogeneity using the I2 statistic; a value of less than 
25% was considered indicative of low heterogeneity.11
Patient and public involvement
As this analysis was based on published data, patients and 
the public were not involved in the design of the study.
ReSulTS
description of included studies
We screened 769 abstracts and 17 full- text reports 
(online supplementary figure 1). We excluded 13 full- 
text reports – four reported on data already included 
in the 2016 review, six were letters or conference 
abstracts, and three had an irrelevant exposure, 
outcome or comparison group.12–24 From a confer-
ence abstract,13 we identified an additional ‘in press’ 
study, which has now been published.25 Therefore, 
five new reports met our inclusion criteria (online 
supplementary table 1).5 25–28 Two reports provided 
the first data from RCTs,5 26 another provided data 
from a new observational analysis,25 and two provided 
additional analyses from previously published obser-
vational studies.27 28 Two RCTs5 26 and two observa-
tional studies25 28 provided direct estimates for the 
association between hormonal contraception and HIV 
acquisition, while three studies (one RCT and two 
observational) examined various factors that might 
modify any association between hormonal contracep-
tive use and HIV risk.5 27 28 One RCT was considered 
“informative with few limitations”,5 and the other 
“unlikely to inform the primary question”.26 The three 
observational studies were rated “informative but with 
important limitations”.25 27 28 Therefore, three new 
reports (from one RCT and two observational studies) 
provided higher- quality (either “informative with few 
limitations” or “informative but with important limita-
tions”) direct evidence about the association between 
hormonal contraceptive use and HIV acquisition.5 25 28
hormonal contraception and risk of hIV infection: new 
RCTs
The ECHO trial provided the first evidence from an 
RCT that was specifically designed to compare HIV 
incidence rates among women using DMPA- IM, LNG 
implants or Cu- IUDs.5 This study did not include a 
group using no contraception. Investigators randomised 
7829 women from 12 sites in four African countries to 
the three contraceptive groups. Participants were aged 
16–35 years, HIV- seronegative, and seeking contra-
ception. Follow- up visits occurred every 3 months for 
up to 18 months and included HIV testing, contra-
ceptive counselling, behavioural assessment, and HIV 
prevention services. Modified intention- to- treat anal-
yses were conducted, along with pre- specified analyses 
restricted to participants with continuous use of the 
assigned contraceptive method and adjusted for poten-
tial confounders including condom use and sexual 
behaviours. Ninety- nine percent of women accepted 
their assigned method, and participants used their 
assigned method for 92% of the follow- up time. More 
than 91% of participants attended each scheduled 
follow- up visit, 99% had at least one follow- up HIV 
test, and the study accumulated 10 409 woman- years 
of follow- up. Overall HIV incidence was 3.81 per 100 
woman- years. No statistically significant differences in 
HIV incidence were observed among the three contra-
ceptive groups in the main modified intention- to–treat 
analysis: HR 1.04 (96% CI 0.82 to 1.33) for DMPA- IM 
compared with Cu- IUD; HR 1.23 (96% CI 0.95 to 
1.59) for DMPA- IM compared with LNG implant, and 
HR 1.18 (96% CI 0.91 to 1.53) for Cu- IUD compared 
with LNG implant. The continuous contraceptive use 
analysis, which adjusted for baseline and time- varying 
covariates, yielded similar results. The ECHO trial was 
considered to be “informative with few limitations” 
because of robust randomisation and allocation proce-
dures, high follow- up and contraceptive continuation 
rates, assessment of condom use and sexual behaviour 
as possible confounders, and appropriate intention- 
to- treat and pre- specified sensitivity analyses. Women 
and providers were not blinded to contraceptive group 
allocation; however, study personnel involved in HIV 
testing were blinded to contraception assignment, 
and the study team worked to ensure that counselling 
messages were consistent across the three groups.
Another open- label RCT was initiated in 2009 but 
stopped early because of plans to conduct the ECHO 
trial.26 This trial randomised women in South Africa 
to receive a Cu- IUD or progestogen- only injectable 
(mostly DMPA, some NET- EN).26 Follow- up was 
planned for 12 months. The analysis included 656 
injectable users and 634 Cu- IUD users who had a 
follow- up HIV test. All of the results presented were 
unadjusted. No increase in HIV seroconversion was 
observed between injectable users and Cu- IUD users 
in the intent- to- treat analysis (risk ratio (RR) 0.88, 
95% CI 0.48 to 1.59) or in the per- protocol analysis 
(RR 0.94, 95% CI 0.52 to 1.71). Separate per- protocol 
risk estimates for DMPA and NET- EN, each compared 
with Cu- IUD, also indicated no association. Although 
this study used appropriate procedures for randomi-
sation and allocation concealment, it was considered 
“unlikely to inform the primary question” because of 
no measurement of condom use, failure to include a 
time- varying analysis of hormonal contraceptive expo-
sure or description of contraceptive discontinuation 
or switching, and the long inter- survey interval for 
assessing HIV seroconversion (median 19–20 months).
hormonal contraception and risk of hIV infection: new 
observational studies
A secondary analysis of an RCT of the dapivirine ring 
to prevent HIV assessed HIV incidence among 1136 
South African study participants using DMPA- IM, 
NET- EN, implants (type not specified) or Cu- IUDs.25 
Contraceptive use, sexual behaviour and other 
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covariates, and HIV infection status were assessed 
during monthly visits. Ninety- five participants sero-
converted over 1771 woman- years of follow- up. In 
contrast to previous observational studies in which 
the non- hormonal contraceptive comparison group 
included a mix of non- hormonal contraceptive use 
and no contraceptive use, this study used Cu- IUD users 
as the non- hormonal contraceptive referent group. 
Overall, there were no statistically significant differ-
ences in HIV incidence among users of the different 
contraceptive methods. When Cu- IUD users formed 
the referent group, the adjusted hazards ratio (adj HR) 
was 0.91 (95% CI 0.44 to 1.87) for DMPA- IM, adj 
HR 1.02 (95% CI 0.49 to 2.12) for NET- EN, adj HR 
0.46 (95% CI 0.13 to 1.70) for implants and adj HR 
0.90 (95% CI 0.45 to 1.76) for all three hormonal 
methods considered together. When NET- EN users 
formed the referent group, the adj HR was 0.89 (95% 
CI 0.55 to 1.44) for DMPA- IM, adj HR 0.45 (95% 
CI 0.13 to 1.53) for implants and adj HR 0.98 (95% 
CI 0.47 to 2.03) for Cu- IUD. This study was consid-
ered “informative but with important limitations”. 
Strengths included time- varying analysis of hormonal 
contraception exposure, condom use, and other rele-
vant confounders; control for trial allocation group 
(dapivirine or placebo); clear exposure and comparison 
groups; and a short inter- survey interval (monthly). 
Limitations included no information on implant type 
(levonorgestrel or etonogestrel), no information about 
attrition within each contraceptive group, and the 
potential for residual or unmeasured confounding.
Another paper provided additional analyses with 
more participants and further follow- up time from the 
Mombasa Cohort, a long- term observational study of 
HIV acquisition among female sex workers in Kenya.28 
Previous analyses had observed that both oral contra-
ceptives (type not specified) and DMPA were associ-
ated with an increased HIV risk compared with no 
contraceptive use.29 LNG implant use was associated 
with an elevated but not statistically significant relative 
risk.30 The new analysis included 1985 women with 
7127 woman- years of follow- up; hormonal contracep-
tion, HIV, and relevant confounders were measured 
monthly. Results for oral contraceptives (adj HR 1.48, 
95% CI 1.05 to 2.09) and DMPA (adj HR 1.72, 95% CI 
1.34 to 2.20), both compared with no contraception, 
were almost identical to the previous results. LNG 
implants were not associated with HIV seroconversion 
(adj HR 0.99, 95% CI 0.40 to 2.45). This study was 
considered “informative with important limitations”, 
primarily because of the potential for unmeasured or 
residual confounding.
hormonal contraceptive use versus non-use in studies 
considered “informative but with important limitations” 
or “informative with few limitations”
Previously, we included 31 observational studies, 
and focused on 14 observational studies considered 
“informative but with important limitations”.2 Results 
from three newly identified publications were of suffi-
cient quality to be added to the forest plots from the 
previous review (figures 1–3 and online supplementary 
figure 2).5 25 28 A new estimate for the head- to- head 
comparison between DMPA- IM and NET- EN use was 
less than unity and not statistically significant,25 unlike 
the statistically significant, above unity, estimates 
from two studies in the previous review; the 95% CIs 
for all three estimates overlapped (figure 4). Finally, 
new head- to- head estimates for implants versus 
NET- EN and DMPA versus LNG implants were added 
(figure 4). The revised meta- analysis of observational 
studies of DMPA compared with non- hormonal or no 
contraception and risk of HIV acquisition resulted in a 
pooled OR of 1.40 (95% CI 1.24 to 1.58) with an I2 of 
0%, indicating low heterogeneity (online supplemen-
tary figure 3); this was almost identical to the pooled 
estimate in the 2016 review.2
effect modification
The previous systematic review did not identify 
consistent factors that modified any association 
between hormonal contraception and HIV acquisition 
(eg, age, herpes simplex virus type 2 (HSV-2), study 
site).2 New data from the ECHO trial found that age 
and HSV-2 status did not modify results comparing 
HIV incidence among the different contraceptive 
methods.5
Two analyses newly assessed bacterial vaginosis (BV) 
as an effect modifier. A cohort study in Zambia27 had 
previously reported no statistically significant associa-
tions for oral contraceptives, DMPA or LNG implant 
use with HIV acquisition.31 The new analysis exam-
ined whether the relationship between hormonal 
contraception and HIV acquisition was modified by 
a BV diagnosis among 564 women in serodiscordant 
couples. In the time- varying analysis, both DMPA (adj 
HR 6.55, 95% CI 1.14 to 37.77) and oral contracep-
tives (adj HR 5.20, 95% CI 1.68 to 16.06) were asso-
ciated with HIV seroconversion during periods when 
BV was diagnosed, each compared with non- hormonal 
or no contraceptive use. No statistically significant 
associations were observed for DMPA (adj HR 1.35, 
95% CI 0.64 to 2.85) or oral contraceptives (adj HR 
1.36, 95% CI 0.76 to 2.42) among women not diag-
nosed with BV. Results were similar when variables for 
sperm on wet- prep and condomless sex in the past 3 
months were added to the model. No incident HIV 
infections occurred among LNG implant users.
In contrast, the updated analysis from the Mombasa 
Cohort Study did not find that BV was an effect modi-
fier.28 DMPA use was associated with increased risk of 
HIV among women with BV (adj HR 1.56, 95% CI 
1.08 to 2.25) and without BV (adj HR 2.08, 1.46–
2.97), each compared with no contraceptive use. Oral 
contraceptive users had an elevated but not statistically 
significant relative risk among women with BV (adj HR 
1.50, 95% CI 0.94 to 2.39) and without BV (adj HR 
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Figure 1 Use of depot medroxyprogesterone acetate (DMPA) (or unspecified injectable) versus non- hormonal or no contraception and HIV acquisition, 
among 14 studies considered “informative but with important limitations” or “informative with few limitations”. Error bars show 95% confidence intervals 
(CIs), with the exception of the ECHO trial which uses 96% CI. Observational studies arranged in order of decreasing magnitude of risk estimate. Graph 
does not display estimates from marginal structural models, except where use of such models resulted in a different conclusions regarding statistical 
significance; in such cases, estimates from both models are displayed on a single line (also identified by bracket signs). Note: restricted to all data on DMPA 
or unspecified injectables, as estimates of unspecified injectables are likely comprised largely of DMPA. *Analysis showed significant findings at p=0.05. 
†Estimate for Cox model taken from slightly updated analysis that controlled for total number of unprotected sex acts. ¶Updated estimate from Baeten et 
al, 2007. ˆUnpublished estimates from a sub- analysis of Morrison 2015 meta- analysis, restricted to pooled analysis using databases not previously used 
to publish estimates on hormonal contraceptive methods and HIV acquisition risk. ¥Different statistical models adjusted for slightly different confounders. 
§Unpublished estimates disaggregated by injectable type. adjHR, adjusted HR; adjIRR, adjusted incidence risk ratio; CI, confidence interval; DMPA, depot 
medroxyprogesterone acetate; ECHO, Evidence for Contraceptive Options and HIV Outcomes Trial; HR, hazard ratio; ITT, intention- to- treat; MSM, marginal 
structural models.
1.61, 95% CI 0.99 to 2.64). LNG implants were not 
associated with HIV seroconversion in either group.
dISCuSSIon
The previous 2016 systematic review concluded that 
new observational evidence at that time increased 
concern about a possible causal association between 
DMPA use and HIV acquisition, although there was 
uncertainty about the potential for unmeasured and 
residual confounding particularly from differential 
condom use or other measures of sexual behaviour.2 
In this update, the addition of results from one new 
observational study,25 and updated results from a 
previously reported observational study,28 did not 
materially change the pattern of risk seen in the forest 
plots or the meta- analysis of observational studies 
suggesting an increased risk of HIV acquisition with 
DMPA use.2 Data from a new RCT, however, do not 
support such a conclusion. 5 The ECHO trial found 
no statistically significant differences in HIV incidence 
among DMPA- IM users when compared with users 
of a non- hormonal method (Cu- IUDs) or LNG 
implant users. This trial provided high- quality, direct 
evidence of HIV risk among users of three contracep-
tive methods. The ECHO trial randomised women 
to contraceptive methods, had low attrition and high 
rates of continuation with the assigned contraceptive 
method, and found similar results of no association 
in both the main modified intention- to- treat analyses 
and secondary sensitivity analyses that controlled for 
several baseline and time- varying factors including 
condomless sex. Therefore, residual confounding 
is unlikely to have affected results from the ECHO 
trial, and so it provides higher- quality evidence about 
whether DMPA increases the risk of HIV acquisition in 
women than that from observational studies.
The ECHO trial observed no increased risk of HIV 
acquisition among LNG implant users when compared 
with Cu- IUD users or DMPA- IM users.5 These findings 
are consistent with three observational studies (two on 
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Figure 2 Use of norethisterone enanthate versus non- hormonal or no contraception and HIV acquisition, among seven studies considered informative but 
with important limitations. Error bars show 95% confidence intervals. Studies arranged in order of decreasing magnitude of risk estimate. Graph does not 
display estimates from marginal structural models. ˆUnpublished estimates from a sub- analysis of Morrison et al. 2015 meta- analysis, restricted to pooled 
analysis using databases not previously used to publish estimates on hormonal contraceptive methods and HIV acquisition risk. §Unpublished estimates 
disaggregated by injectable type. adjHR, adjusted HR; adjIRR, adjusted incidence risk ratio; CI, confidence interval; HR, hazard ratio; NET- EN, norethisterone 
enanthate.
LNG implants and one on unspecified implants) that 
found no increased risk of HIV acquisition among 
implant users compared with non- hormonal contra-
ceptive users.25 28 31 The study of unspecified implants 
also observed a statistically non- significant reduced risk 
of HIV among implant users compared with NET- EN 
users, which had not been assessed previously.25
The ECHO trial did not examine NET- EN, and 
therefore information on NET- EN and HIV acquisi-
tion came solely from observational studies. Previ-
ously, six studies examined HIV acquisition among 
NET- EN users compared with non- hormonal users, 
with none finding a statistically significant association; 
a newly identified seventh study reported an estimate 
consistent with those findings.25 Two observational 
studies had previously found an increased risk of HIV 
acquisition among DMPA users directly compared 
with NET- EN users,2 an association not observed in a 
newly identified study.25
The assessment of oral contraceptive use and HIV 
risk was also based only on evidence from observa-
tional studies. The overall body of evidence continues 
to suggest no increased risk of HIV among oral contra-
ceptive users; the only new evidence was an updated 
estimate that was nearly identical to the previously 
included estimate from the same study.28
The previous review did not identify any consistent 
factors that modify the relationship between hormonal 
contraceptive use and HIV acquisition.2 Neither age 
nor HSV-2 status were modifiers in the ECHO trial.5 
Two studies assessed for the first time whether BV is 
an effect modifier,27 28 with conflicting results. Differ-
ences between the two studies included the populations 
studied (women in serodiscordant couples27 and female 
sex workers28), BV diagnostic techniques, measurement 
of potential confounders, and overall findings (ie, one 
study observed an association between hormonal contra-
ception and HIV but did not find effect modification by 
BV,28 while the study that did not find an overall associ-
ation suggested effect modification).27
Although a new RCT has provided high- quality 
evidence about the incidence of HIV among users of 
two hormonal contraceptive methods, most of the body 
of evidence remains based on observational studies. 
The limitations of the observational data on this topic 
have been described in detail.2 32 33 Key concerns are 
unmeasured and residual confounding, as well as 
unclear exposure and outcome measurement, and lack 
of time- varying measures in analysis. We continue to 
urge caution when interpreting the meta- analysis results 
from observational studies of DMPA and HIV acquisi-
tion, given important uncertainties about each study 
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Figure 3 Use of implants* (versus non- hormonal or no contraception) and HIV acquisition, among four studies considered “informative but with 
important limitations” or “informative with few limitations”. Error bars show 95% confidence intervals (CIs), with the exception of the ECHO trial which 
uses 96% CI. Studies arranged in order of decreasing magnitude of risk estimate. *Sabo et al, Wall et al and the ECHO trial included levonorgestrel implants; 
Palanee- Phillips et al did not specify implant type. **The ECHO trial reported an adjHR 1.18 (96% CI 0.91 to 1.53) for the comparison of copper intrauterine 
devices (Cu- IUDs) versus levonorgestrel (LNG) implant. The inverse association is represented on this figure for LNG implant versus Cu- IUD. adjHR, adjusted 
HR; CI, confidence interval; ECHO, Evidence for Contraceptive Options and HIV Outcomes Trial; HR, hazard ratio; ITT, intention- to- treat.
included in the meta- analysis and the potential for 
spurious precision. For RCTs, proper randomisation 
should equalise confounding factors among groups at 
baseline. However, unblinded follow- up of participants 
provides opportunities for confounding and other biases 
to occur, for example through changes in contraceptives 
used or differential condom use by contraceptive group 
because of knowledge of the initial contraceptive allo-
cated. Such changes need to be captured and allowed 
for in time- varying analyses, as was done in the ECHO 
trial.5 Although the ECHO trial was not designed to 
answer the question of whether any of the contraceptive 
methods assessed increased the risk of HIV acquisition 
when compared with no contraceptive method use, the 
high rates of HIV infection observed among the study 
groups were similar to the underlying incidence used 
when designing the trial. This finding provides indirect 
evidence of no increased risk of HIV acquisition among 
DMPA- IM, Cu- IUD or LNG implant users, compared 
with women using no contraception. Finally, unan-
swered questions remain about hormonal contracep-
tive methods for which there is currently no evidence, 
including DMPA- SC, etonogestrel implants, LNG- IUDs 
and non- oral forms of combined hormonal methods.
An earlier version of this review, which included 
observational studies and RCTs published before the 
ECHO trial, was considered during a 2019 WHO 
Guideline Development Group Meeting to assess 
recommendations on contraception for women at 
high risk of HIV acquisition. WHO’s updated guid-
ance states that women at high risk of acquiring HIV 
infection are eligible to use all hormonal contraceptive 
methods and IUDs without restriction.34
ConCluSIonS
New high- quality evidence from an RCT (the ECHO 
trial) did not find an increased risk of HIV among 
women using DMPA compared with LNG implant or 
Cu- IUD users.5 These RCT data provided high- quality 
evidence about whether DMPA use increases HIV risk, 
as they are less likely to be confounded than findings 
from observational studies. As concluded in previous 
reviews, the body of evidence suggests no increased 
risk of HIV acquisition associated with use of other 
hormonal contraceptive methods.
Additional educational resources
WHO Guidance on Hormonal Contraceptive Eligi-
bility for Women at High Risk of HIV https://www. 
who. int/ reproductivehealth/ publications/ contracep-
tive- eligibility- women- at- high- risk- of- HIV/ en/
WHO Medical Eligibility Criteria for Contraceptive 
Use https://www. who. int/ reproductivehealth/ publica-
tions/ family_ planning/ Ex- Summ- MEC- 5/ en/
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Figure 4 Hormonal contraceptive methods and HIV acquisition in head- to- head studies, among four studies considered “informative but with important 
limitations” or “informative with few limitations”. Error bars show 95% confidence intervals (CIs), with the exception of the ECHO trial which uses 
96% CI. Within each comparison group, studies are arranged in order of decreasing magnitude of risk estimate. *Analysis showed significant findings at 
p=0.05. **Results from randomised clinical trial; all other results from observational studies. adjHR, adjusted HR; CI, confidence interval; COC, combined 
oral contraception; ECHO, Evidence for Contraceptive Options and HIV Outcomes Trial; DMPA, depot medroxyprogesterone acetate; HR, hazard ratio; LNG, 
levonorgestrel; NET- EN, norethisterone enanthate.
WHO Selected Practice Recommendations for 
Contraceptive Use https://www. who. int/ reproductive-
health/ publications/ family_ planning/ SPR- 3/ en/
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